An investigational once-weekly amylin receptor agonist conferred substantial weight loss across six different dosing regimens for adults with overweight or obesity, researchers reported in a phase 2 ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to ...

Novo Nordisk (NYSE:NVO) shares have drawn attention recently as investors look for clues about what might be driving the stock's movement this month. In the absence of major headlines, valuation and ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

The bears will point out that Novo Nordisk is losing ground in the GLP-1 market to its most important competitor, Eli Lilly.

The analysts see “meaningful skew to the downside” as around one-third of Roche’s 2030 revenue is at risk from competitors targeting major franchises such as Vabysmo, Perjeta, Hemlibra, Alecensa, and ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Competition ...

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the firm disclosed data at the annual meeting of the American Diabetes ...

Amycretin — a novel experimental molecular targeting both the glucagon-like peptide 1 (GLP-1) and the amylin receptor — has shown promise for weight management in early-phase clinical trials.

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly ...